A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

• Karthik Ramasamy,
• Ajay Nooka,
• Hang Quach,
• Myo Htut,
• Rakesh Popat,
• Michaela Liedtke,
• Sascha A. Tuchman,
• Jacob Laubach,
• Cristina Gasparetto,
• Asher Chanan-Khan,
• Mark Hertzberg,
• Mark deMario,
• Eveline Nueesch,
• Evelyne Chesne,
• Izolda Franjkovic,
• Katharina Lechner,
• Martin Kornacker,
• Hearn Jay Cho

Affiliations

Karthik Ramasamy

Department of Haematology, Oxford University Hospital, NHS Trust

Ajay Nooka

Winship Cancer Institute, Emory University

Hang Quach

University of Melbourne, St. Vincent’s Hospital

Myo Htut

City of Hope Comprehensive Cancer Center

Rakesh Popat

University College London Hospitals, NHS Foundation Trust

Michaela Liedtke

Stanford University Cancer Center

Sascha A. Tuchman

Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina

Jacob Laubach

Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Cristina Gasparetto

Department of Medicine, Duke Univ. Medical Center

Asher Chanan-Khan

Division of Hematology and Medical Oncology, Mayo Clinic

Mark Hertzberg

Department of Clinical Haematology, Prince of Wales Hospital

Mark deMario

Roche Pharma Research and Early Development

Eveline Nueesch

Roche Innovation Center Basel, Roche Pharma Research and Early Development

Evelyne Chesne

Roche Innovation Center Basel, Roche Pharma Research and Early Development

Izolda Franjkovic

Roche Innovation Center Munich, Roche Pharma Research and Early Development

Katharina Lechner

Roche Innovation Center Munich, Roche Pharma Research and Early Development

Martin Kornacker

Roche Innovation Center Basel, Roche Pharma Research and Early Development

Hearn Jay Cho

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai